PRAXIS PRECISION MEDICINES, INC. (PRAX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 290.71M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 45.81M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -378.17M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $290.71M | (m) | $45.81M | $-378.17M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $284.30M | (m) | $42.27M | $-357.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $267.12M | $0.00 | $33.94M | $-326.20M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $245.90M | $7.46M | $32.58M | $-293.11M | (m) | 3294.88% | 436.53% | (m) | (m) |
| 2025-06-30 | $221.98M | $7.76M | $37.56M | $-271.59M | (m) | 2858.74% | 483.75% | (m) | (m) |
| 2025-03-31 | $186.24M | $8.12M | $35.67M | $-233.01M | (m) | 2292.97% | 439.19% | (m) | (m) |
| 2024-12-31 | $152.41M | $8.55M | $41.36M | $-200.16M | (m) | 1781.98% | 483.57% | (m) | (m) |
| 2024-09-30 | $114.51M | $1.60M | $38.51M | $-164.01M | (m) | 7134.77% | 2399.44% | (m) | (m) |
| 2024-06-30 | $89.89M | $1.77M | $31.84M | $-132.70M | (m) | 5075.78% | 1797.97% | (m) | (m) |
| 2024-03-31 | $88.25M | $2.19M | $31.74M | $-130.17M | (m) | 4020.32% | 1445.97% | (m) | (m) |
| 2023-12-31 | $86.77M | $2.45M | $24.86M | $-126.37M | (m) | 3545.81% | 1015.82% | (m) | (m) |
| 2023-09-30 | $96.71M | (m) | $25.50M | $-140.02M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $109.89M | (m) | $26.46M | $-158.79M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $127.89M | (m) | $28.30M | $-184.23M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $155.04M | (m) | $28.59M | $-214.99M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $170.22M | (m) | $28.33M | $-232.19M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $172.92M | (m) | $28.12M | $-232.67M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $154.98M | (m) | $25.91M | $-208.76M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $120.26M | (m) | $22.69M | $-167.33M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $93.02M | (m) | $20.41M | $-134.39M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $72.67M | (m) | $14.85M | $-105.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $56.04M | (m) | $9.73M | $-80.92M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $44.98M | (m) | $5.21M | $-61.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $29.56M | (m) | $668.00K | $-35.79M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |